SILO

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Silo Pharma regains Nasdaq compliance, signals PTSD trial progress

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Silo Pharma announced it regained compliance with the Nasdaq minimum bid price rule as of June 17, 2026, resolving a listing concern and keeping its Nasdaq Capital Market listing intact. The company also stressed ongoing momentum toward a first-in-human trial for SPC-15 targeting PTSD and the development of its AI agents platform QwikAgents, underscoring potential near-term clinical milestones and value creation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Silo regained Nasdaq bid-price compliance as of June 17, 2026.</li><li>Stock remains listed on Nasdaq Capital Market; matter now closed.</li><li>CEO cites progress toward SPC-15 PTSD trial and QwikAgents AI platform.</li><li>Portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia, and Alzheimer&#039;s preclinical asset.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Silo Pharma, Inc. (SILO)</strong>: Regained Nasdaq bid-price compliance as of June 17, 2026; progress toward SPC-15 PTSD and QwikAgents.</li><li><strong>Nasdaq, Inc. (NDAQ)</strong>: Regulatory body referenced for listing rules; context for Nasdaq compliance announcements.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The update centers on regulatory/listing status and near-term execution milestones, which can influence liquidity, investor confidence, and potential valuation support for SILO.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regaining Nasdaq bid-price compliance reduces delisting risk and improves liquidity.</li><li>Progress toward SPC-15 PTSD trial could unlock pipeline value.</li><li>QwikAgents AI platform advancement may attract partnerships or licensing interest.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of compliance regain: June 17, 2026.</li><li>Press release date: June 18, 2026.</li><li>Lead program: SPC-15 for PTSD.</li><li>Other assets: SP-26 for fibromyalgia; preclinical Alzheimer&#039;s asset.</li><li>Company focus: developmental-stage biopharmaceuticals with university collaborations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish near-term on compliance and SPC-15 progress, with potential upside over the next 1–3 quarters.</p>
  </section>
</section>


<article>
  <section>
    <h2>Silo Pharma Regains Nasdaq Minimum Bid Price Compliance</h2>
    <p>SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SILO">SILO</a>) (<em>"Silo"</em> or <em>"the Company"</em>), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of <strong>June 17, 2026</strong>, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule <strong>5550(a)(2)</strong>. Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.</p>
  </section>

  <section>
    <h3>Executive Commentary</h3>
    <p>"We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a <em>first-in-human clinical trial</em> of our lead drug SPC-15 targeting PTSD and successfully advancing our <em>AI agents platform QwikAgents</em>," said Eric Weisblum, Chief Executive Officer of Silo Pharma.</p>
  </section>

  <section>
    <h3>About Silo Pharma, Inc.</h3>
    <p><strong>About Silo Pharma, Inc.</strong><br></br>Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease. Silo's research is conducted in collaboration with leading universities and laboratories. <a href="https://www.globenewswire.com/Tracker?data=D8qvhaoGGtVZfxV5MdvFRG1zwBWnuNgVNc2jTt4ViGmb0cT8qsdipZv9GVUEJQ4y_VnC3xlAhTcHjURHKRry2Q==" rel="nofollow" target="_blank">silopharma.com</a></p>
  </section>

  <section>
    <h3>Forward-Looking Statements</h3>
    <p>This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</p>
  </section>

  <section>
    <h3>Contact</h3>
    <p>(800) 705-0120<br></br><a href="https://www.globenewswire.com/Tracker?data=gw59hAX1_er4XQRdY3L1xQNdYJfU1nRZzMptxRCoRhRDUJ2bhLQBygAcWpa4Z5Gf2sXTATarpdPBXtWr9rnaM3SA4LkLp88Et2vnoZyiulQLD0F4db5di4y_y031vejT" rel="nofollow" target="_blank">investors@silopharma.com</a></p>
  </section>
</article>

Silo Pharma announced it regained compliance with the Nasdaq minimum bid price rule as of June 17, 2026, resolving a listing concern and keeping its Nasdaq Capital Market listing intact. The company also stressed ongoing momentum toward a first-in-human trial for SPC-15 targeting PTSD and the development of its AI agents platform QwikAgents, underscoring potential near-term clinical milestones and value creation.

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News